lifitegrast

Glaucoma, dry eye drugs center of pharmaceutical opportunitiesThe pharma drought is coming to a close. After decades of same-old medications for glaucoma and ocular surface disease, a series of new agents with new mechanisms of action (MOA) are moving toward marketing approval.
Shire utilizing biotech approach to meet unmet ophthalmic needsShire, which built its experience in biotech agents, is taking a biotech approach to meeting unmet needs in both the anterior and poster segments of ophthalmology.
Lifitegrast data support dry eye efficacy over placebo dropsLifitegrast ophthalmic solution 0.05% (Xiidra, Shire) has demonstrated positive results for the treatment of the signs and symptoms of dry eye disease. Eye dryness scores for some patients have improved after two weeks of treatment with the topical drop.
Dry eye gains importance in glaucoma careNew treatments and greater awareness are making dry eye an even more important part of glaucoma care, according to Richard Lewis, MD, of Sacramento Eye Consultants.
New dry eye treatment demonstrates rapid onset symptomatic reliefResults from the Phase 3 OPUS-3 trial provide evidence confirming a benefit of lifitegrast ophthalmic solution 5.0% (Xiidra, Shire) for significantly improving dry eye disease-related symptoms, as measured by Eye Dryness Score.
Shire gets FDA nod for Xiidra (lifitegrast) for dry eye
Shire gets FDA nod for Xiidra (lifitegrast) for dry eyeShire plc obtained U.S. Food and Drug Administration (FDA) approval for Xiidra (lifitegrast ophthalmic solution) 5%, a twice-daily eye drop indicated for the treatment of the signs and symptoms of dry eye disease in adult patients.
Shire's FDA-approved drug ends dry eye treatment drought
Shire's FDA-approved drug ends dry eye treatment droughtOphthalmologists have been waiting more than a decade for a new treatment option for their dry eye patients—and the anticipation is finally over. Lifitegrast ophthalmic solution 5% (Xiidra, Shire Ophthalmics) is a twice-daily eye drop solution and is the only FDA-approved drug indicated to treat the signs and symptoms of dry eye disease, according to the company.
Topical integrin antagonist lifitegrast safely treats dry eye diseaseLifitegrast ophthalmic solution 5.0% (Shire Pharmaceuticals) administered twice daily for 1 year appeared safe and well-tolerated with no unexpected adverse events in a study.
Ocular surface therapy and mydriasis focus of 2014An examination of the advancements made in drug therapy this past year includes ocular surface therapy, the approval of an anti-inflammatory mydriatic agent, and several dry eye drugs.
Lifitegrast promising for patients using artificial tearsJohn Sheppard, MD, highlights results of a phase III randomized, double-masked, placebo-controlled trial of lifitegrast in dry eye patients previously on artificial tears. He presented these results, a subset analysis of the OPUS-1 phase III trial, at the 2013 meeting of the American Society of Cataract and Refractive Surgery.